Advertisement
Canada markets open in 1 hour 38 minutes
  • S&P/TSX

    22,468.16
    +2.79 (+0.01%)
     
  • S&P 500

    5,321.41
    +13.28 (+0.25%)
     
  • DOW

    39,872.99
    +66.22 (+0.17%)
     
  • CAD/USD

    0.7314
    -0.0022 (-0.30%)
     
  • CRUDE OIL

    77.93
    -0.73 (-0.93%)
     
  • Bitcoin CAD

    95,695.70
    -1,960.13 (-2.01%)
     
  • CMC Crypto 200

    1,518.20
    -8.22 (-0.54%)
     
  • GOLD FUTURES

    2,412.30
    -13.60 (-0.56%)
     
  • RUSSELL 2000

    2,098.36
    -4.14 (-0.20%)
     
  • 10-Yr Bond

    4.4140
    -0.0230 (-0.52%)
     
  • NASDAQ futures

    18,801.50
    +2.25 (+0.01%)
     
  • VOLATILITY

    12.14
    +0.28 (+2.36%)
     
  • FTSE

    8,377.76
    -38.69 (-0.46%)
     
  • NIKKEI 225

    38,617.10
    -329.83 (-0.85%)
     
  • CAD/EUR

    0.6754
    0.0000 (0.00%)
     

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

Clearside Biomedical, Inc.
Clearside Biomedical, Inc.

ALPHARETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time, in New York, NY.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.